A Phase 2 interventional study of bevacizumab [Avastin] and eloxatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-06.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 87th largest by enrollment of the 224 interventional ones that give a count, is one of 25 that started in 2006, is one of 133 in phase 2, and was the 89th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Gilead Sciences · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Oncolytics Biotech · Sites in United States
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 150 · Phase 3 48 · Phase 4 8
First in 2000; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 224 interventional studies. Of the 144 that completed or were terminated, 50 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 230 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 40th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2006, is one of 32 in phase 2, and was the 42nd registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
14 of the studies testing bevacizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT07007728Peking University Cancer Hospital & InstituteIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | 2026-12-31 |
| NCT03401294University of SaskatchewanConversion From Unresectable To Resectable Metastatic Colorectal Cancer. | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of a first-line regimen of Avastin and Xelox (Xeloda + Eloxatin) followed by Avastin and Tarceva, in patients with metastatic colorectal cancer. Patients will receive 6 x 21 day cycles of treatment with Avastin (7.5mg/kg iv on day 1), Xeloda (1000mg/m2 po twice daily on days 1 to 14) and Eloxatin (130mg/m2 iv on day 1). Patients free of disease progression will then continue with Avastin (7.5mg/kg iv once every 3 weeks) and Tarceva (150mg po daily). The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: eloxatin · Drug: capecitabine [Xeloda] · Drug: erlotinib [Tarceva]
Intravenous repeating dose
Intravenous repeating dose
Oral repeating dose
Oral repeating dose
Percentage of Participants With Disease Progression or Death
Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Start of study to approximately 4 years
Progression-Free Survival
Progression-free survival was defined as the time from the date of informed consent until the date when the participant had progression of disease or died from disease progression. Participants who received surgical treatment after treatment ended were censored at the time of surgery. Participants who left the study for reasons other than progression of the disease were censored on the date on which they received a later antitumor therapy (with the same or different drugs, radiotherapy, or surgery).
Time frame: From study start up to approximately 4 years
Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR])
Percentage of participants with objective response based assessment of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]) and no new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: From study start up to approximately 4 years
Percentage of Participants Achieving Disease Control (CR, PR, or No Change [NC])
Percent of participants with confirmed CR, PR, or NC. Per RECIST version (v)1.0: CR was defined as disappearance of all target and non-target lesions. PR was defined as ≥30% decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions. NC was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non-target lesions.
Time frame: From study start up to approximately 4 years
Percentage of Participants Who Died
Time frame: From study start up to approximately 4 years
Overall Survival (OS)
Overall survival was defined as the time from the date of informed consent to the date of death (regardless of the cause of death). There was no restriction; survival was calculated until the date of death, even if another line of treatment was received, or until the date censored (last contact with the participant even if drugs different from the study treatment schedule were received). For all participants, survival information was collected until the date of death, the last contact, or the last follow-up.
Time frame: From study start up to approximately 4 years
| Milestone | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Started | 90 |
| Completed | 0 |
| Not completed | 90 |
| Withdrew: Adverse event | 20 |
| Withdrew: Progressive disease | 38 |
| Withdrew: Investigator judgement | 25 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Death | 1 |
| Withdrew: Ongoing at time of analysis | 2 |
Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.
| percentage of participants | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Percentage of Participants With Disease Progression or Death | 61.1 |
Percentage of participants with objective response based assessment of CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]) and no new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) | 55.95 |
Percent of participants with confirmed CR, PR, or NC. Per RECIST version (v)1.0: CR was defined as disappearance of all target and non-target lesions. PR was defined as ≥30% decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions. NC was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference smallest sum of longest dimensions since treatment started associated to non-progressive disease response for non-target lesions.
| percentage of participants | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Percentage of Participants Achieving Disease Control (CR, PR, or No Change [NC]) | 92.86 |
| percentage of participants | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Percentage of Participants Who Died | 58.89 |
Progression-free survival was defined as the time from the date of informed consent until the date when the participant had progression of disease or died from disease progression. Participants who received surgical treatment after treatment ended were censored at the time of surgery. Participants who left the study for reasons other than progression of the disease were censored on the date on which they received a later antitumor therapy (with the same or different drugs, radiotherapy, or surgery).
| months | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Progression-Free Survival | 9.18 (7.86 to 11.87) |
Overall survival was defined as the time from the date of informed consent to the date of death (regardless of the cause of death). There was no restriction; survival was calculated until the date of death, even if another line of treatment was received, or until the date censored (last contact with the participant even if drugs different from the study treatment schedule were received). For all participants, survival information was collected until the date of death, the last contact, or the last follow-up.
| months | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Overall Survival (OS) | 25.79 (17.99 to 30.92) |
Collected over Participants were monitored for adverse events (AEs) from the first dose of study drug until the end of the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib | — | 33/90 (36.7%) | 89/90 (98.9%) |
| Event | Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 18/90 |
| AstheniaGeneral disorders | 11/90 |
| NeutropeniaBlood and lymphatic system disorders | 7/90 |
| RashSkin and subcutaneous tissue disorders | 6/90 |
| VomitingGastrointestinal disorders | 4/90 |
| HypertensionVascular disorders | 4/90 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/90 |
| AcneSkin and subcutaneous tissue disorders | 3/90 |
| Deep vein thrombosisVascular disorders | 3/90 |
| AnaemiaBlood and lymphatic system disorders | 2/90 |
| Event | Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| AstheniaGeneral disorders | 69/90 |
| DiarrhoeaGastrointestinal disorders | 56/90 |
| NauseaGastrointestinal disorders | 41/90 |
| RashSkin and subcutaneous tissue disorders | 38/90 |
| VomitingGastrointestinal disorders | 36/90 |
| AnorexiaMetabolism and nutrition disorders | 35/90 |
| ParaesthesiaNervous system disorders | 35/90 |
| NeurotoxicityNervous system disorders | 32/90 |
| Abdominal painGastrointestinal disorders | 31/90 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 29/90 |
Intent-to-treat (ITT) population: all enrolled participants.
| Age, Continuous(years) | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Mean | 59.23 ± 8.18 |
| Sex: Female, Male(Participants) | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab+Erlotinib |
|---|---|
| Female | 29 |
| Male | 61 |
The record gives a start of Nov 2006, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Oxaliplatin · Capecitabine · Erlotinib